XML 22 R14.htm IDEA: XBRL DOCUMENT
v3.25.3

Equity Method Investments | 9 Months Ended
--- | ---
Sep. 30, 2025
Equity Method Investments and Joint Ventures [Abstract] |
Equity Method Investments | Note 6 – Equity Method Investments In November 2018, CPFH LLC, of which the Company holds a 25% share, was formed to purchase certain real estate assets among partners in a joint venture. In March 2020, HGC Origination I LLC and HGC Funding I LLC were formed as joint ventures with a partner for purposes of conducting business relating to the sourcing, origination and funding of loans to debt purchasing clients. In April 2022, KNFH LLC, of which the Company holds a 25% share, was formed to purchase certain real estate assets and machinery and equipment among partners in a joint venture. In December 2022, DHC8 LLC, of which the Company holds a 13.33% share was formed to provide funding and receive principal and interest payments as a result of the initial investment. In May 2023, HGC MPG Funding LLC, of which the Company holds a 25% share, was formed as a joint venture with a partner for purposes of conducting business relating to the sourcing, origination and funding of loans to debt purchasing clients. In December 2023, KNFH II LLC, of which the Company holds a 25% share, was formed to purchase certain real estate assets and machinery and equipment among partners in a joint venture. In January 2025, DLZ Solutions LLC ("DLZ"), a joint venture in which the Company holds a 20% share, entered into a purchase agreement to purchase certain real estate assets and a lease agreement to lease back the purchased real estate assets to the seller. CPFH LLC, KNFH LLC, DHC8 LLC, KNFH II LLC, and DLZ are joint ventures formed in connection with the Company’s Industrial Assets division, whereas HGC Origination I LLC, HGC Funding I LLC, and HGC MPG Funding LLC were formed in connection with the Financial Assets division. The Company has significant influence over the operations and financial policies of each of its equity method investments. In accordance with ASC 326, the Company performs a review of notes receivable on a quarterly basis for each of its specialty lending investments. During the nine months ended September 30, 2025, the Company made no material adjustment for its share of the joint venture’s provision for credit losses. As of September 30, 2025, the Company's share of the allowance for credit losses was primarily related to HGC Origination I LLC and HGC MPG Funding LLC. As of September 30, 2025, the Company has incurred no actual credit losses through its equity method investments. As of September 30, 2025, the amortized cost basis of the Company's share of loans in nonaccrual status recorded in equity method investments was $17.5 million. The table below details the Company’s joint venture revenues, earnings, assets, and liabilities for the nine months ended and as of September 30, 2025 (in thousands):
|  | DHC8 LLC |  |  | KNFH II LLC |  |  | DLZ Solutions LLC |  |  | HGC Funding I LLC and Origination I LLC |  |  | HGC MPG Funding LLC |  |  | Total |
Revenue |  | $ | 140 |  |  | $ | (8 | ) |  | $ | 488 |  |  | $ | 3,511 |  |  | $ | 4,134 |  |  | $ | 8,264 |
Gross profit |  |  | 140 |  |  |  | (8 | ) |  |  | 488 |  |  |  | 3,511 |  |  |  | 4,134 |  |  |  | 8,264 |
Operating income (loss) |  |  | 54 |  |  |  | (158 | ) |  |  | 368 |  |  |  | 3,489 |  |  |  | 4,116 |  |  |  | 7,870 |
Net income (loss) |  |  | 54 |  |  |  | (158 | ) |  |  | 368 |  |  |  | 3,494 |  |  |  | 4,116 |  |  |  | 7,875 |
Assets |  |  | 67 |  |  |  | 7,270 |  |  |  | 8,298 |  |  |  | 23,135 |  |  |  | 29,830 |  |  |  | 68,601 |
Liabilities |  |  | 67 |  |  |  | 2,038 |  |  |  | 143 |  |  |  | 5 |  |  |  | — |  |  |  | 2,252 |
The table below details the Company’s joint venture revenues, earnings, assets, and liabilities for the nine months ended and as of September 30, 2024 (in thousands):
|  | DHC8 LLC |  |  | KNFH II LLC |  |  | HGC Funding I LLC and Origination I LLC |  |  | HGC MPG Funding LLC |  |  | Total |
Revenues |  | $ | 751 |  |  | $ | 13,249 |  |  | $ | 3,705 |  |  | $ | 3,987 |  |  | $ | 21,692 |
Gross profit |  |  | 751 |  |  |  | 5,213 |  |  |  | 3,705 |  |  |  | 3,987 |  |  |  | 13,656 |
Operating income |  |  | 590 |  |  |  | 5,120 |  |  |  | 3,656 |  |  |  | 3,987 |  |  |  | 13,353 |
Net income |  |  | 590 |  |  |  | 5,120 |  |  |  | 3,656 |  |  |  | 3,987 |  |  |  | 13,353 |
Assets |  |  | 2,068 |  |  |  | 7,966 |  |  |  | 26,113 |  |  |  | 33,066 |  |  |  | 69,213 |
Liabilities |  |  | 1,038 |  |  |  | — |  |  |  | 972 |  |  |  | — |  |  |  | 2,010 |
Lessor Arrangements In December 2023, the Company, with certain partners making up the KNFH II LLC joint venture, entered into a purchase and sale agreement for a pharmaceutical plant in Fenton, Missouri, including land, a building, and all machinery and equipment held within, with a purchase price of $8.0 million. In April 2024, KNFH II LLC entered into a purchase and sale agreement for the machinery and equipment within the pharmaceutical plant with a purchase price of $5.0 million. Additionally, KNFH II LLC entered into a lease agreement for the lease of the real estate assets; the building and land. This lease agreement includes a purchase option with a purchase price of $8.0 million that is expected to be exercised by the lessee. The lessor arrangement is classified as a sales-type lease, and, therefore, the present value of future lease payments, including the purchase option, has been recognized as revenue and a lease receivable as of the effective date. As of September 30, 2025, the Company recognized approximately $1.2 million in life-to-date earnings of equity method investments, related to the Company’s share of net income attributable to KNFH II LLC. On January 29, 2025, DLZ, a joint venture in which the Company holds a 20% share, entered into a purchase agreement for a pharmaceutical plant in Huntsville, Alabama, including land and a building, with a purchase price of approximately $7.8 million. Simultaneously, DLZ entered into a lease agreement with the Seller, for the lease of the real estate assets, the building and land. This lease agreement includes a purchase option exercisable prior to the end of the first 18-month lease term with a purchase price of approximately $9.7 million. Concurrently, the Company sold a one-third economic interest in cash flows related to the DLZ investment, which is reflected as a secured borrowing on its balance sheet within other non-current liabilities. As of September 30, 2025, the Company has recorded approximately $74,000 in earnings in equity method investments and approximately $25,000 in cost of services revenue related to the investment on the consolidated statement of income. Additionally, on January 29, 2025, the Company purchased a 20% participating interest in a financial asset for approximately $1.6 million. The participants’ investment was used to purchase machinery and equipment at the same pharmaceutical plant in Huntsville, Alabama for approximately $7.8 million. The participants entered into a lease agreement to lease the purchased machinery and equipment back to the seller with an 18-month lease term which includes purchase option exercisable prior to the end of the term with a purchase price of approximately $9.5 million. As of September 30, 2025, the Company reflects its participating interest of $1.5 million on its balance sheet within other long-term assets. Concurrently, the Company sold a one-third economic interest in cash flows related to its participating interest, which is reflected as a secured borrowing on its balance sheet within other non-current liabilities. As of September 30, 2025, the Company has recorded approximately $77,000 in services revenue and approximately $26,000 in costs of services revenue related to the investment on the consolidated statement of income.

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + References Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 323 -Publisher FASB -URI https://asc.fasb.org/323/tableOfContent + Details
Name: | us-gaap_EquityMethodInvestmentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration